Clinical Rheumatology

, Volume 26, Issue 9, pp 1475–1480 | Cite as

Surgical outcomes and risk factors for postoperative complications in patients with Behcet’s disease

  • Min-Chan Park
  • Bum-Kee Hong
  • Hyuck Moon Kwon
  • You-Sun Hong
Original Article


This study aims to investigate surgical outcomes in patients with Behcet’s disease (BD) and to identify risk factors for the occurrence of postoperative complications. The medical records of 37 patients with newly diagnosed BD were reviewed retrospectively. All patients fulfilled the International Study Group criteria for diagnosis of BD and underwent surgeries after diagnosis. Demographic, clinical, and laboratory data at the time when surgeries were performed were collected and surgical modalities, postoperative complications, and postoperative medical treatments were evaluated. Forty-three surgeries were performed in 37 patients. During mean follow-up duration of 78.2 ± 50.3 months, 14 surgeries (32.6%) were complicated by wound dehiscence, infection, and graft occlusion or failure with the mean lag time of 6.0 ± 4.6 months from surgeries. Cumulative incidence of postoperative complications was 7.7% at 3 months, 25.6% at 6 months, 33.3% at 12 months, and 35.9% at 18 months. Postoperative complications occurred more frequently after surgeries that were performed in patients with positive pathergy test (P < 0.001) and after vascular surgeries than after nonvascular surgeries (P < 0.05). Moreover, surgeries that were followed by glucocorticoids with immunosuppressive agents showed a significantly lower postoperative complication rate compared to those that were followed by glucocorticoids alone and those that were not followed by medical treatment (P < 0.05). Multivariate analysis showed that a positive pathergic reaction (P < 0.05, hazard ratio = 1.91) at the time of surgery and surgeries that were not followed by treatment with glucocorticoids and immunosuppressive agent (P < 0.01, hazard ratio = 2.11) was an independent risk factor for the occurrence of postoperative complications. Our findings suggest that the occurrence of postoperative complications can be reduced when postsurgical immunosuppressive treatment was implemented and that the pathergy test can be used as screening methods for occurrence of postoperative complications in patients with BD.


Behcet’s disease Immunosuppressive treatment Pathergy test Postoperative complications Risk factor Surgery 



The authors wish to thank Sung Min Myoung, Ph.D., Department of Biostatistics, Yonsei University College of Medicine, for his statistical consultation.


  1. 1.
    Sakane T, Takeno M, Suzuki N, Inaba G (1999) Current concepts: Behcet’s disease. N Engl J Med 341:1284–1291PubMedCrossRefGoogle Scholar
  2. 2.
    Suzuki Kurokawa M, Suzuki N (2004) Behcet’s disease. Clin Exp Med 4:10–20PubMedCrossRefGoogle Scholar
  3. 3.
    Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76PubMedCrossRefGoogle Scholar
  4. 4.
    O’Duffy JD (1990) Vasculitis in Behcet’s disease. Rheum Dis Clin North Am 16:423–431PubMedGoogle Scholar
  5. 5.
    Duzgun N, Ates A, Aydintug OT, Demir O, Olmez U (2006) Characteristics of vascular involvement in Behcet’s disease. Scand J Rheumatol 35:65–68PubMedCrossRefGoogle Scholar
  6. 6.
    Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C (2005) Behcet’s disease and cardiovascular involvement. Lupus 14:723–726PubMedCrossRefGoogle Scholar
  7. 7.
    Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H (1996) Gastrointestinal involvement in Behcet’s syndrome: a controlled study. Ann Rheum Dis 55:208–210PubMedGoogle Scholar
  8. 8.
    Jorizzo JL, Solomon AR, Cavallo T (1985) Behcet’s syndrome. Immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up. Arch Pathol Lab Med 109:747–751PubMedGoogle Scholar
  9. 9.
    Ehrlich GE (1997) Vasculitis in Behcet’s disease. Int Rev Immunol 14:81–88PubMedGoogle Scholar
  10. 10.
    Al-Mutawa SA, Hegab SM (2004) Behcet’s disease. Clin Exp Med 4:103–131PubMedCrossRefGoogle Scholar
  11. 11.
    Bradbury AW, Milne AA, Murie JA (1994) Surgical aspects of Behcet’s disease. Br J Surg 81:1712–1721PubMedCrossRefGoogle Scholar
  12. 12.
    Ozeren M, Mavioglu I, Dogan OV, Yucel E (2000) Reoperation results of arterial involvement in Behcet’s disease. Eur J Vasc Endovasc Surg 20:512–516PubMedCrossRefGoogle Scholar
  13. 13.
    Iscan ZH, Vural KM, Bayazit M (2005) Compelling nature of arterial manifestations in Behcet disease. J Vasc Surg 41:53–58PubMedCrossRefGoogle Scholar
  14. 14.
    Hosaka A, Miyata T, Shigematsu H, Shigematsu K, Okamoto H, Ishii S et al (2005) Long-term outcome after surgical treatment of arterial lesions in Behcet disease. J Vasc Surg 42:116–121PubMedCrossRefGoogle Scholar
  15. 15.
    International Study Group for Behcet’s disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080Google Scholar
  16. 16.
    Ando M, Kosakai Y, Okita Y, Nakano K, Kitamura S (1999) Surgical treatment of Behcet’s disease involving aortic regurgitation. Ann Thorac Surg 68:2136–2140PubMedCrossRefGoogle Scholar
  17. 17.
    Tuzun H, Besirli K, Sayin A, Vural FS, Hamuryudan V, Hizli N et al (1997) Management of aneurysms in Behcet’s syndrome: an analysis of 24 patients. Surgery 121:150–156PubMedCrossRefGoogle Scholar
  18. 18.
    Le Thi Huong D, Wechsler B, Papo T, Piette JC, Bletry O, Vitoux JM et al (1995) Arterial lesions in Behcet’s disease. A study in 25 patients. J Rheumatol 22:2103–2113PubMedGoogle Scholar
  19. 19.
    Kwon Koo B, Shim WH, Yoon YS, Kwon Lee B, Choi D, Jang Y et al (2003) Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Behcet’s disease. J Endovascular Ther 10:75–80CrossRefGoogle Scholar
  20. 20.
    Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet’s disease. J Am Acad Dermatol 24:973–978PubMedCrossRefGoogle Scholar
  21. 21.
    Davatchi F, Shahram F, Chams H, Akbarian N, Nadji A, Gharibdoost C et al (1998) Methotrexate for ocular lesions of Behcet’s disease. Cohort study on 262 patients. Arthritis Rheum 41(suppl):S356Google Scholar
  22. 22.
    Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T (1985) Pathologic features of Behcet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol 16:790–795PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • Min-Chan Park
    • 1
  • Bum-Kee Hong
    • 2
  • Hyuck Moon Kwon
    • 2
  • You-Sun Hong
    • 3
  1. 1.Division of Rheumatology, Department of Internal Medicine, Yongdong Severance HospitalYonsei University College of MedicineSeoulSouth Korea
  2. 2.Division of Cardiology, Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea
  3. 3.Department of Thoracic and Cardiovascular SurgeryYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations